XTL Biopharma files to raise $40m on Nasdaq
CEO Shlomo Yanai tells "Globes" about the venture with P&G, and Teva's expansion in Russia and Japan.
"The ability to sell more products through more channels in more regions means that within a few years we'll reach $4 billion in sales, compared with current sales of $1.2 billion by the two companies," Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) president and CEO Shlomo told "Globes" today on the launch of the company's joint over-the-counter drugs venture with Procter & Gamble Company NYSE: PG), PGT Healthcare.
PGT Healthcare will operate worldwide, except for North America. Teva will contribute its development and production skills and its current products line, while Procter & Gamble will contribute its brand and marketing skills. Although Teva owns 49% of the joint venture, it will recognize half of its revenue, because it will provide the production services. As part of the venture, Procter & Gamble sold its OTC plants in North Carolina and Arizona to Teva.
The announcement of the joint venture earlier this year took the markets by surprise, as the OTC drug market had never before been a core business of Teva. "The global healthcare consumer market is estimated at $200 billion," Yanai told "Globes". "The OTC segment of this market, in contrast to vitamins and nutritional supplements, is a full pharmaceutical industry, subject to regulatory approval."
Yanai points to several factors that will drive the OTC market in the coming years. "The middle class is growing rapidly, and people with greater awareness about health and quality of life want to be more involved in the purchasing, and they have buying power. This consumer class is also seeking a shopping experience. Instead of waiting for a doctor, tests, obtaining a prescription, and then waiting at a pharmacy, things are much simpler for OTC products."
Yanai adds, "Another element is government budgets. Although direct purchasing ought to be more expensive because there is no subsidizing group, such as an HMO, from an economic perspective, there are cost savings in time for consumers, doctors, and pharmacists. Government costs are also lower, so there is an incentive driving the market forward. For all these reasons, we expect the OTC market to grow.
"Until now, Teva and Procter & Gamble's OTC businesses did not create value, but were part of the sales turnover. Our link-up has the immediate potential by combining our product lines, supplemental geographical deployments, and more sales channels. For example, until now Teva has not sold to retailers, and Procter & Gamble did not sell to pharmacies."
"Globes": Which drugs are targeted for development and marketing by the joint venture?
Yanai: "There is a very large upside from the switch of prescription products to OTC products. More products will be switched in the coming years. For example, there is no reason why cholesterol-lowering statin drugs, which almost any adult can take, shouldn’t be an OTC product. Not to mention other products. This is basically the venture's good news."
The joint venture with Procter & Gamble is one more item in Teva's strategic plan to diversify and expand operations to reduces Teva's current dependence on its sole brand drug, Copaxone, and to prepare for the day after the multiple sclerosis drug. The strategy includes expanding to new markets, one of which is Russia.
Looking to Russia
Six weeks ago, Teva announced its initial $50 million investment to build a production plant in Yaroslavl. The plant is due to produce two billion tablets a year when it comes on line in 2014, and it will employ 200 people. Teva also plans to invest $300 million in production and R&D in Russia over the next few years. Russian Prime Minister Vladimir Putin was present at the plant's cornerstone laying ceremony.
Construction of the Yaroslavl plant fits in with the Russian government's program to encourage medical production and development in the country, and Teva will likely participate in the second, R&D, stage of the program. "There are tax breaks - that isn't an Israeli invention, and the breaks in most of the world are better than in Israel. Every country offers tax breaks to attract foreign investment," says Yanai, explaining the benefits for the company.
"The Russian market has great potential. It's a Great Power, an emerging market, with a population of almost 150 million, and an improving economic situation thanks to its natural resources. The market potential is in the billions."
With such potential, Teva naturally has something to strive for. Its current sales in Russia total $500 million a year, and its generic sales in the third quarter rose 27%. In contrast to other markets where Teva's growth is based on acquisitions, its growth in Russia in recent years has been organic. Seven years ago, Teva was not among Russia's top 20 pharmaceutical companies; today it's the fourth or fifth largest company in the sector. Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ) is no. 1.
Will Teva acquire Russian companies?
"It's very hard to answer that. Acquisitions are made when there's a strategic decision to enter a market, or if there's an extraordinary opportunity. At the moment, there are no plans to make an acquisition because we're satisfied with our organic growth in Russia, but the option is open."
Expanding in Japan
Three years after setting a Japanese joint venture with Kowa Company Ltd., Teva-Kowa Pharma, Teva bought out its partner for $150 million in September to pursue the venture alone. Two months earlier, it acquired Taiyo Pharmaceutical Industry Co. Ltd. for $934 million in cash.
Yanai concluded, "When we entered the market, we wanted the help of a local party, which understands the market. After a couple of years, we wanted to make an acquisition to make a big move in the market, which is the second largest in the world. Our partner, for its own reasons did not want to participate, so we made the acquisition alone. We wanted to buy out Kowa in the joint venture because it's hard to carry out separate operations, one with a partner and one without, and obtain the maximum synergy. The separation was amicable."
Published by Globes [online], Israel business news - www.globes-online.com - on November 3, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
You comment was recieved and soon will be published.
Load more comments
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.